Literature DB >> 21266708

Validation of intravascular ultrasound-derived parameters with fractional flow reserve for assessment of coronary stenosis severity.

Soo-Jin Kang1, Jong-Young Lee, Jung-Min Ahn, Gary S Mintz, Won-Jang Kim, Duk-Woo Park, Sung-Cheol Yun, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park.   

Abstract

BACKGROUND: We assessed optimal intravascular ultrasound (IVUS) criteria for predicting functional significance of intermediate coronary lesions. METHODS AND
RESULTS: Overall, 201 patients with 236 coronary lesions underwent IVUS and invasive physiological assessment before intervention. Fractional flow reserve (FFR) was measured at maximal hyperemia induced by intravenous adenosine infusion. FFR <0.80 at maximum hyperemia was seen in 49 (21%) of the overall 236 lesions. The independent determinants of FFR were minimal lumen area (MLA; β=0.020; 95% confidence interval [CI], 0.008 to 0.031; P=0.032), plaque burden (β=-0.002; 95% CI, -0.003 to 0.001; P=0.001), lesion length with a lumen area <3.0 mm(2) (β=-0.003; 95% CI, -0.005 to -0.001; P=0.005), and left anterior descending artery location (β=-0.035; 95% CI, -0.055 to -0.016; P=0.001). The best cutoff value (with a maximal accuracy) of the MLA to predict FFR <0.80 was <2.4 mm(2), with a diagnostic accuracy of 68% (90% sensitivity, 60% specificity, and area under the curve=0.800; 95% CI, 0.742 to 0.848; P<0.001). The cutoff value of plaque burden to predict FFR <0.80 was ≥79% (69% sensitivity, 72% specificity, and area under the curve=0.756; 95% CI, 0.696 to 0.810; P<0.001). The cutoff value of lesion length with a lumen area <3.0 mm(2) was 3.1 mm (84%sensitivity, 63%specificity, and area under the curve=0.765; 95% CI, 0.706 to 0.818; P<0.001). Among 117 lesions with an MLA ≥2.4 mm(2), 112 (96%) had an FFR ≥0.80,; and all but 1 showed FFR ≥0.75. Conversely, 44 (37%) lesions with an MLA <2.4 mm(2) had an FFR <0.80.
CONCLUSIONS: IVUS-derived MLA ≥2.4 mm(2) may be useful to exclude FFR <0.80, but poor specificity limits its value for physiological assessment of lesions with MLA <2.4 mm(2). Thus, FFR or stress tests may be necessary to accurately identify ischemia-inducible intermediate stenoses.

Entities:  

Mesh:

Year:  2011        PMID: 21266708     DOI: 10.1161/CIRCINTERVENTIONS.110.959148

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  32 in total

1.  Method for percutaneously introducing, and removing, anatomical stenosis of predetermined severity in vivo: the "stenotic stent".

Authors:  Nicolas Foin; Sayan Sen; Ricardo Petraco; Sukhjinder Nijjer; Ryo Torii; Chrysa Kousera; Christopher Broyd; Vikram Mehta; Yun Xu; Jamil Mayet; Alun Hughes; Carlo Di Mario; Rob Krams; Darrel Francis; Justin Davies
Journal:  J Cardiovasc Transl Res       Date:  2013-06-04       Impact factor: 4.132

2.  Optical coherence tomography criteria for defining functional severity of intermediate lesions: a comparative study with FFR.

Authors:  Tomasz Pawlowski; Francesco Prati; Tomasz Kulawik; Eleonora Ficarra; Jacek Bil; Robert Gil
Journal:  Int J Cardiovasc Imaging       Date:  2013-09-03       Impact factor: 2.357

Review 3.  A systematic review of imaging anatomy in predicting functional significance of coronary stenoses determined by fractional flow reserve.

Authors:  Miao Chu; Neng Dai; Junqing Yang; Jelmer Westra; Shengxian Tu
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-06       Impact factor: 2.357

Review 4.  Impact of plaque characteristics on the degree of functional stenosis.

Authors:  Pedro de Araújo Gonçalves; Alexandre Hideo-Kajita; Hector Manuel Garcia-Garcia
Journal:  Cardiovasc Diagn Ther       Date:  2017-04

5.  Comparison between minimum lumen cross-sectional area and intraluminal ultrasonic intensity analysis using integrated backscatter intravascular ultrasound for prediction of functionally significant coronary artery stenosis.

Authors:  Hironori Takami; Shinjo Sonoda; Yoshitaka Muraoka; Toshiya Miura; Akiyoshi Shimizu; Reo Anai; Yoshinori Sanuki; Tetsu Miyamoto; Yasushi Oginosawa; Yoshihisa Fujino; Yuki Tsuda; Masaru Araki; Yutaka Otsuji
Journal:  Heart Vessels       Date:  2018-07-30       Impact factor: 2.037

6.  Effect of myocardial contractility on hemodynamic end points under concomitant microvascular disease in a porcine model.

Authors:  Srikara Viswanath Peelukhana; Kranthi K Kolli; Massoud A Leesar; Mohamed A Effat; Tarek A Helmy; Imran Arif; Eric W Schneeberger; Paul Succop; Rupak K Banerjee
Journal:  Heart Vessels       Date:  2013-04-30       Impact factor: 2.037

Review 7.  Use of intravascular imaging in managing coronary artery disease.

Authors:  Sanda Jegere; Inga Narbute; Andrejs Erglis
Journal:  World J Cardiol       Date:  2014-06-26

8.  Evaluation and medical therapy for coronary endothelial dysfunction induced by sirolimus-eluting stent in patient with an atherosclerotic lesion of the left main coronary artery: Case report.

Authors:  Hiroyuki Tabata; Satoshi Yoshino; Kenta Ohmure; Daichi Fukumoto; Hirokazu Shimono; Yoshihiro Uchikado; Shigeki Tateishi; Mitsuru Ohishi
Journal:  J Cardiol Cases       Date:  2017-09-22

9.  What is an appropriate reference standard in the quantitation of plaque surface area by intravascular coronary ultrasound?

Authors:  Charles L Laham; Matthew J McMahon; Michael S Chandra; Roy Venzon; Michael Jerin; Nicolas W Shammas
Journal:  Int J Angiol       Date:  2012-03

10.  Prospective, head-to-head comparison of quantitative coronary angiography, quantitative computed tomography angiography, and intravascular ultrasound for the prediction of hemodynamic significance in intermediate and severe lesions, using fractional flow reserve as reference standard (from the ATLANTA I and II Study).

Authors:  Szilard Voros; Sarah Rinehart; Jesus G Vazquez-Figueroa; Anna Kalynych; Dimitri Karmpaliotis; Zhen Qian; Parag H Joshi; Hunt Anderson; Laura Murrieta; Charles Wilmer; Harold Carlson; William Ballard; Charles Brown
Journal:  Am J Cardiol       Date:  2013-10-02       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.